MedTrace Logo

Study of NST-6179 in Healthy Subjects

NCT05181085 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2024-06-24

Study results available
· View outcomes & findings →

Summary

A double-blind, randomized, placebo controlled, single and multiple oral dose study to assess safety and tolerability of single and multiple doses of NST-6179 in healthy male and female subjects.

Conditions

  • Short Bowel Syndrome
  • Parenteral Nutrition Associated Liver Disease

Interventions

DRUG

NST 6179

orally administered, fully synthetic medium chain fatty acid (MCFA) analogue

DRUG

Placebo

inactive analogue

Sponsors & Collaborators

  • NorthSea Therapeutics B.V.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-11-11
Primary Completion
2022-05-27
Completion
2022-05-27

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05181085 on ClinicalTrials.gov